Concepts (105)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 6 | 2024 | 272 | 2.370 |
Why?
|
| Head and Neck Neoplasms | 3 | 2022 | 1052 | 1.160 |
Why?
|
| Metals | 2 | 2016 | 90 | 1.080 |
Why?
|
| Cone-Beam Computed Tomography | 2 | 2016 | 64 | 1.070 |
Why?
|
| Radiotherapy, Image-Guided | 3 | 2020 | 56 | 0.970 |
Why?
|
| Radiation Pneumonitis | 1 | 2022 | 21 | 0.860 |
Why?
|
| Chemoradiotherapy | 3 | 2022 | 301 | 0.840 |
Why?
|
| Pneumonia | 1 | 2022 | 179 | 0.760 |
Why?
|
| Fiducial Markers | 1 | 2020 | 7 | 0.740 |
Why?
|
| Phantoms, Imaging | 2 | 2020 | 429 | 0.730 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2017 | 383 | 0.680 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2020 | 176 | 0.660 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2023 | 930 | 0.660 |
Why?
|
| Artifacts | 2 | 2016 | 244 | 0.620 |
Why?
|
| Movement | 1 | 2020 | 299 | 0.610 |
Why?
|
| Dental Restoration, Permanent | 1 | 2016 | 2 | 0.580 |
Why?
|
| Dental Implants | 1 | 2016 | 10 | 0.570 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 1075 | 0.570 |
Why?
|
| Software | 1 | 2020 | 654 | 0.540 |
Why?
|
| Lung Neoplasms | 3 | 2022 | 2262 | 0.530 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 1195 | 0.470 |
Why?
|
| Algorithms | 2 | 2016 | 1830 | 0.400 |
Why?
|
| Neoplasms | 2 | 2023 | 2898 | 0.380 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 1076 | 0.370 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 1721 | 0.330 |
Why?
|
| Organ Sparing Treatments | 2 | 2017 | 38 | 0.300 |
Why?
|
| Radiation Oncology | 2 | 2020 | 119 | 0.290 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 1939 | 0.290 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 1056 | 0.270 |
Why?
|
| Humans | 15 | 2024 | 86643 | 0.240 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 582 | 0.230 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2024 | 69 | 0.230 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2020 | 1204 | 0.210 |
Why?
|
| Cetuximab | 1 | 2022 | 113 | 0.200 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2022 | 98 | 0.200 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2021 | 28 | 0.200 |
Why?
|
| Databases, Factual | 3 | 2022 | 814 | 0.200 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2020 | 173 | 0.200 |
Why?
|
| Odontogenic Tumors | 1 | 2020 | 11 | 0.190 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2021 | 66 | 0.190 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2020 | 73 | 0.190 |
Why?
|
| Organs at Risk | 1 | 2020 | 41 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 2601 | 0.180 |
Why?
|
| Immunotherapy | 2 | 2022 | 629 | 0.180 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 1686 | 0.180 |
Why?
|
| Cystectomy | 2 | 2017 | 102 | 0.170 |
Why?
|
| Cytokines | 1 | 2023 | 776 | 0.170 |
Why?
|
| Radiotherapy | 2 | 2020 | 328 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 860 | 0.170 |
Why?
|
| Radiotherapy Dosage | 1 | 2020 | 468 | 0.170 |
Why?
|
| Bone Neoplasms | 1 | 2021 | 322 | 0.160 |
Why?
|
| Disease-Free Survival | 2 | 2020 | 1204 | 0.160 |
Why?
|
| Aged | 4 | 2020 | 18415 | 0.160 |
Why?
|
| Male | 6 | 2020 | 40965 | 0.150 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 736 | 0.150 |
Why?
|
| Retrospective Studies | 4 | 2021 | 8489 | 0.150 |
Why?
|
| Carcinoma | 1 | 2020 | 436 | 0.150 |
Why?
|
| Oncologists | 1 | 2017 | 36 | 0.150 |
Why?
|
| Propensity Score | 1 | 2017 | 136 | 0.150 |
Why?
|
| Radiation Oncologists | 1 | 2016 | 13 | 0.140 |
Why?
|
| Societies, Medical | 1 | 2020 | 572 | 0.140 |
Why?
|
| Treatment Outcome | 2 | 2020 | 7993 | 0.140 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 6509 | 0.140 |
Why?
|
| Confidence Intervals | 1 | 2016 | 229 | 0.140 |
Why?
|
| Geriatric Assessment | 1 | 2017 | 166 | 0.140 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 292 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 552 | 0.130 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2017 | 164 | 0.130 |
Why?
|
| Analysis of Variance | 1 | 2017 | 912 | 0.130 |
Why?
|
| Urinary Bladder | 1 | 2017 | 246 | 0.130 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 859 | 0.130 |
Why?
|
| Observer Variation | 1 | 2016 | 602 | 0.130 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 999 | 0.120 |
Why?
|
| Prospective Studies | 1 | 2022 | 4213 | 0.120 |
Why?
|
| Prognosis | 2 | 2021 | 3679 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2017 | 1538 | 0.120 |
Why?
|
| Radiographic Image Enhancement | 1 | 2015 | 462 | 0.110 |
Why?
|
| Female | 5 | 2020 | 44532 | 0.110 |
Why?
|
| Middle Aged | 4 | 2020 | 25028 | 0.110 |
Why?
|
| Time Factors | 1 | 2020 | 5210 | 0.100 |
Why?
|
| Adult | 3 | 2020 | 25648 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2017 | 2767 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2017 | 2261 | 0.090 |
Why?
|
| United States | 4 | 2020 | 6672 | 0.070 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2024 | 155 | 0.060 |
Why?
|
| Physics | 1 | 2020 | 22 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2020 | 289 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2020 | 180 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2020 | 217 | 0.040 |
Why?
|
| Research | 1 | 2020 | 253 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 486 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 257 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 266 | 0.040 |
Why?
|
| Comorbidity | 1 | 2020 | 943 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 1239 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 364 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 865 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1851 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 3640 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1036 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1464 | 0.030 |
Why?
|
| Risk Factors | 1 | 2020 | 5417 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 2501 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 2438 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 5976 | 0.020 |
Why?
|